STOCK TITAN

Tiziana Life Sciences Ltd - TLSA STOCK NEWS

Welcome to our dedicated news page for Tiziana Life Sciences (Ticker: TLSA), a resource for investors and traders seeking the latest updates and insights on Tiziana Life Sciences.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Tiziana Life Sciences's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Tiziana Life Sciences's position in the market.

-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
18.46%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.33%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.06%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.5%
Tags
buyback
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.74%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.05%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.94%
Tags
conferences
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.64%
Tags
none
Tiziana Life Sciences Ltd

Nasdaq:TLSA

TLSA Rankings

TLSA Stock Data

45.54M
61.41M
43.47%
0.78%
0.36%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United Kingdom
London

About TLSA

tiziana life sciences plc is a uk biotechnology company that focuses on the discovery and development of novel molecules that treat human disease in oncology and immunology. the company is focused on its lead compound, milciclib, a molecule which blocks the action of specific enzymes called cyclin-dependent kinases (cdk) involved in cell division as well as a number of other protein kinases. milciclib is currently in phase ii clinical trials for thymic carcinoma in patients previously treated with chemotherapy. the company is also in clinical development of foralumab. foralumab is the only fully human engineered anti-human cd3 antibody in clinical development. this phase ii compound has potential application in a wide range of autoimmune and inflammatory diseases, such as ulcerative colitis, multiple sclerosis, type-1 diabetes (t1d), inflammatory bowel disease (ibd), psoriasis and rheumatoid arthritis, where modulation of a t-cell response is desirable. tiziana life sciences’ research